(Q42964146)

11 November 2017

0 references

Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin (English)

1 reference

Erratum to: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin

11 November 2017

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1186/BCR1786

author

Graham Colditz

series ordinal

1

1 reference

11 November 2017

1 January 2007

1 reference

11 November 2017

Breast Cancer Research

1 reference

11 November 2017

9

1 reference

11 November 2017

4

1 reference

11 November 2017

108

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr1736

11 November 2017

0 references

cites work

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

The decrease in breast-cancer incidence in 2003 in the United States

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Breast cancer and hormone-replacement therapy in the Million Women Study

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Rising incidence of breast cancer: relationship to stage and receptor status

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Trends in incidence rates of invasive lobular and ductal breast carcinoma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206710

Breast cancer and hormone-replacement therapy: the Million Women Study

16 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR1736

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR1736

Postmenopausal estrogens--opposed, unopposed, or none of the above

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17666116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17666116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The decreasing incidence of endometrial cancer: public health implications

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17666116

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR1736

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference

11 November 2017

PubMed publication ID

17666116

1 reference